[Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast]

Shinichiro Kashiwagi,Tomohisa Okuno,Sae Ishihara,Mariko Ishii,Yuka Asano,Mao Watanabe,Tamami Morisaki,Naoki Aomatsu,Satoru Noda,Hidemi Kawajiri,Taeko Nakano,Noriko Kawakami,Yasuko Mitsukawa,Tsutomu Takashima,Naoyoshi Onoda,Tetsuro Ishikawa,Kosei Hirakawa

Abstract:The patient was a 40-year-old woman who was aware of a tumor in her left breast that was gradually increasing in size. Ultrasonography revealed a hypoechoic mass with a skin cyst, approximately 3 cm in size, in the C area of the left breast. Core needle biopsy indicated estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and human epidermal growth factor receptor 2 (HER2) -negative squamous cell carcinoma. Overall examination did not indicate distant metastasis. A diagnosis of T4bN2aM0, stage IIIB triple-negative left breast cancer was made. Eribulin was administered at a dose of 1.4 mg/m2. The effect of eribulin was considered to be long-term stable disease( long-term SD). The patient did not experience severe adverse events during treatment. After 24 weeks of eribulin treatment, mastectomy of the left breast with axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that eribulin chemotherapy is useful for the treatment of patients with squamous cell carcinoma of the breast.